Picture loading failed.

Anti-CD79B therapeutic antibody (Pre-made Polatuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Polatuzumab vedotin contains a monoclonal antibody that binds to a protein called CD79B, which is found on B cells (a type of white blood cell) and some lymphoma cells. It also contains an anticancer drug, which may help kill cancer cells. Polatuzumab vedotin is a type of antibody-drug conjugate. Also called Polivy.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-449-1mg 1mg Inquiry
GMP-Bios-ab-449-10mg 10mg Inquiry
GMP-Bios-ab-449-100mg 100mg Inquiry
GMP-Bios-ab-449-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD79B therapeutic antibody (Pre-made Polatuzumab biosimilar,Whole mAb ADC)
INN Name Polatuzumab
TargetCD79B
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesChugai Pharmaceutical;Genentech;Roche
Conditions ApprovedDiffuse large B cell lymphoma
Conditions ActiveNon-Hodgkin's lymphoma;Follicular lymphoma
Conditions DiscontinuedChronic lymphocytic leukaemia
Development Techna